Pieter Smits

Showing 1-20 of 23 articles

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial

Smits P, Chang C, Chevalier B, West N, Gori T, Barbato E, Tarantini G, Kocka V, Achenbach S, Dudek D, Escaned J, Wlodarczak A, Abdel-Wahab M, Esposito G, Tijssen J, Morice M, Onuma Y, van Geuns R

October 23, 2020 | 10.4244/EIJ-D-19-01079

Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial

Smits P, Laforgia P, Abdel-Wahab M, Neumann F, Richardt G, Boxma-de Klerk B, Lunde K, Schotborgh C, Piroth Z, Horak D, Wlodarczak A, Frederix G, Omerovic E

June 25, 2020 | 10.4244/EIJ-D-20-00012

Coronary interventions

The obesity paradox revisited: body mass index and long-term outcomes after PCI from a large pooled patient-level database

Wolny R, Maehara A, Liu Y, Zhang Z, Mintz G, Redfors B, Madhavan M, Smits P, von Birgelen C, Serruys P, Mehran R, Leon M, Stone G

January 17, 2020 | 10.4244/EIJ-D-19-00467

Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention

Brener S, Leon M, Serruys P, Smits P, von Birgelen C, Mehran R, Kirtane A, Witzenbichler B, Rinaldi M, Metzger C, Mazzaferri E, Zhang Z, Stone G

August 9, 2019 | 10.4244/EIJ-D-19-00262

Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy

Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Iñiguez A, Janssens L, Smits P, Wykrzykowska J, Ribeiro V, Pereira H, da Silva P, Piek J, Reiber J, von Birgelen C, Sabaté M, Onuma Y, Serruys P

August 3, 2018 | 10.4244/EIJ-D-17-00461

Stents and scaffolds

A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial

Paradies V, Ben-Yehuda O, Jonas M, Banai S, Iñiguez A, Perlman G, Kandzari D, Stone G, Smits P

May 20, 2018 | 10.4244/EIJ-D-17-00890

First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial

von Birgelen C, Asano T, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernández-Antolín R, van de Harst P, Iñiguez A, Janssens L, Smits P, Wykrzykowska J, Ribeiro V, Pereira H, da Silva P, Piek J, Onuma Y, Serruys P, Sabaté M

April 20, 2018 | 10.4244/EIJ-D-17-00462

Coronary interventions

Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions

Fam J, Ojeda S, Garbo R, Latib A, La Manna A, Vaquerizo B, Boukhris M, Vlachojannis G, van Geuns R, Ezhumalai B, Kawamoto H, van der Sijde J, Felix C, Pan M, Serdoz R, Boccuzzi G, De Paolis M, Sardella G, Mancone M, Tamburino C, Smits P, Di Mario C, Seth A, Serra A, Colombo A, Serruys P, Galassi A, Zijlstra F, Van Mieghem N, Diletti R

June 20, 2017 | 10.4244/EIJ-D-16-00253

Coronary interventions

Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months

Felix C, Vlachojannis G, IJsselmuiden A, Fam J, Smits P, Lansink W, Diletti R, Zijlstra F, Regar E, Boersma E, Onuma Y, van Geuns R

June 2, 2017 | 10.4244/EIJ-D-17-00119

Coronary interventions

Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials

Vlachojannis G, Puricel S, Natsuaki M, Morimoto T, Smits P, Kimura T

March 20, 2017 | 10.4244/EIJ-D-16-00773

Coronary interventions

Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial

Chevalier B, Onuma Y, Van Boven A, Piek J, Sabaté M, Helqvist S, Baumbach A, Smits P, Kumar R, Wasungu L, Serruys P

October 20, 2016 | 10.4244/EIJY16M08_01

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial

Vlachojannis G, Smits P, Hofma S, Togni M, Vázquez N, Valdes M, Voudris V, Puricel S, Slagboom T, Goy J-J, den Heijer P, van der Ent M

July 20, 2015 | 10.4244/EIJV11I3A53

Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

Hofma S, Smits P, Brouwer J, Velders M, van’t Hof A, Quere M, de Vries C, Van Boven A

March 20, 2015 | 10.4244/EIJY15M01_03

Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)

Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C, Veldhof S, Regar E, Serruys P, van Geuns R

June 20, 2014 | 10.4244/EIJV10I2A38

Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J

March 20, 2014 | 10.4244/EIJV9I11A217

STEMI patients and non-culprit lesions: what to do and when?

Smits P

December 27, 2013 | 10.4244/EIJV9I8A150

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P

October 25, 2013 | 10.4244/EIJV9I6A115

A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients

Vranckx P, Verheugt F, de Maat MP, Ulmans V, Regar E, Smits P, ten Berg J, Lindeboom W, Jones R, Friedman J, Reilly P, Leebeek F

January 18, 2013 | 10.4244/EIJV8I9A162

Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials

Kedhi E, Stone G, Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P

September 28, 2012 | 10.4244/EIJV8I5A92

Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial

Kedhi E, Gomes M, Joesoef K, Wassing J, Goedhart D, McFadden E, Smits P, investigators t

April 20, 2012 | 10.4244/EIJV7I12A217

Latest news

NEW ISSUE

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

News

Don’t Miss #EIJOnAir 2nd Edition!

Elective cardiac invasive procedures during the COVID-19 outbreak

March 4, 2021

Ahead of Print

MitraClip for a range of LV dysfunction and secondary MR

Stamatios Lerakis et al.

March 2, 2021

Editorial

Thrombolysis in ST-elevation myocardial infarction is not dead

Petr Kala et al.

March 2, 2021

SCOPE 2, COACT 1 year, FORZA, COMPARE CRUSH

(Thanks to the support of Biotronik)

February 28, 2021

JAA

This Week's JAA's: Impact of crossing strategy on CTO recanalisation outcomes and more...

March 2, 2021

Guidance Papers

Guidelines, consensus & position papers